BR112020025111A2 - Motivo de interação amiloide geral (gaim) - Google Patents
Motivo de interação amiloide geral (gaim) Download PDFInfo
- Publication number
- BR112020025111A2 BR112020025111A2 BR112020025111-9A BR112020025111A BR112020025111A2 BR 112020025111 A2 BR112020025111 A2 BR 112020025111A2 BR 112020025111 A BR112020025111 A BR 112020025111A BR 112020025111 A2 BR112020025111 A2 BR 112020025111A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- seq
- amyloidosis
- amyloid
- gaim
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685757P | 2018-06-15 | 2018-06-15 | |
| US62/685,757 | 2018-06-15 | ||
| US201862749499P | 2018-10-23 | 2018-10-23 | |
| US62/749,499 | 2018-10-23 | ||
| PCT/US2019/037179 WO2019241628A1 (en) | 2018-06-15 | 2019-06-14 | General amyloid interaction motif (gaim) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020025111A2 true BR112020025111A2 (pt) | 2021-04-06 |
Family
ID=67263052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020025111-9A BR112020025111A2 (pt) | 2018-06-15 | 2019-06-14 | Motivo de interação amiloide geral (gaim) |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11692017B2 (https=) |
| EP (2) | EP3806884B1 (https=) |
| JP (1) | JP7549536B2 (https=) |
| CN (1) | CN112672755A (https=) |
| AU (1) | AU2019287623B2 (https=) |
| BR (1) | BR112020025111A2 (https=) |
| ES (1) | ES2960493T3 (https=) |
| IL (1) | IL279333B2 (https=) |
| MX (1) | MX2020013525A (https=) |
| PL (1) | PL3806884T3 (https=) |
| SG (1) | SG11202012091WA (https=) |
| WO (1) | WO2019241628A1 (https=) |
| ZA (1) | ZA202100071B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241628A1 (en) * | 2018-06-15 | 2019-12-19 | Proclara Biosciences, Inc. | General amyloid interaction motif (gaim) |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| AU2023403257A1 (en) | 2022-12-02 | 2025-06-12 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
| CN117343200B (zh) * | 2023-12-04 | 2024-01-30 | 北京质肽生物医药科技有限公司 | 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| CA2857539C (en) | 2011-11-29 | 2021-08-03 | Neurophage Pharmaceuticals, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| AU2014274253B2 (en) | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| BR112017011530A2 (pt) | 2014-12-03 | 2018-03-13 | Proclara Biosciences Inc | polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação |
| WO2019241628A1 (en) * | 2018-06-15 | 2019-12-19 | Proclara Biosciences, Inc. | General amyloid interaction motif (gaim) |
-
2019
- 2019-06-14 WO PCT/US2019/037179 patent/WO2019241628A1/en not_active Ceased
- 2019-06-14 BR BR112020025111-9A patent/BR112020025111A2/pt unknown
- 2019-06-14 AU AU2019287623A patent/AU2019287623B2/en active Active
- 2019-06-14 ES ES19739769T patent/ES2960493T3/es active Active
- 2019-06-14 SG SG11202012091WA patent/SG11202012091WA/en unknown
- 2019-06-14 EP EP19739769.8A patent/EP3806884B1/en active Active
- 2019-06-14 CN CN201980049538.2A patent/CN112672755A/zh active Pending
- 2019-06-14 JP JP2020569166A patent/JP7549536B2/ja active Active
- 2019-06-14 PL PL19739769.8T patent/PL3806884T3/pl unknown
- 2019-06-14 EP EP23188404.0A patent/EP4389154A3/en active Pending
- 2019-06-14 MX MX2020013525A patent/MX2020013525A/es unknown
- 2019-06-14 US US17/251,351 patent/US11692017B2/en active Active
-
2020
- 2020-12-09 IL IL279333A patent/IL279333B2/en unknown
-
2021
- 2021-01-05 ZA ZA2021/00071A patent/ZA202100071B/en unknown
-
2023
- 2023-05-19 US US18/320,697 patent/US12247055B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3806884T3 (pl) | 2023-11-20 |
| CN112672755A (zh) | 2021-04-16 |
| MX2020013525A (es) | 2021-02-26 |
| US11692017B2 (en) | 2023-07-04 |
| ES2960493T3 (es) | 2024-03-05 |
| CA3102841A1 (en) | 2019-12-19 |
| US20230279064A1 (en) | 2023-09-07 |
| IL279333B2 (en) | 2023-06-01 |
| EP3806884A1 (en) | 2021-04-21 |
| AU2019287623B2 (en) | 2024-11-07 |
| US20210246179A1 (en) | 2021-08-12 |
| ZA202100071B (en) | 2023-04-26 |
| IL279333A (en) | 2021-01-31 |
| SG11202012091WA (en) | 2021-01-28 |
| EP4389154A3 (en) | 2024-11-13 |
| US12247055B2 (en) | 2025-03-11 |
| EP4389154A2 (en) | 2024-06-26 |
| JP2021527407A (ja) | 2021-10-14 |
| AU2019287623A1 (en) | 2021-01-07 |
| EP3806884C0 (en) | 2023-08-02 |
| WO2019241628A1 (en) | 2019-12-19 |
| EP3806884B1 (en) | 2023-08-02 |
| JP7549536B2 (ja) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12247055B2 (en) | General amyloid interaction motif (GAIM) | |
| TWI613212B (zh) | 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白 | |
| US20240000971A1 (en) | Compositions and methods for the treatment of tauopathy | |
| JP2020073610A (ja) | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド | |
| BR112014013086A2 (pt) | Composições para tratamento de doença associada com proteína amiloide agregada epara detectar ou gerar imagem de amiloide agregada e uso das referidas composições | |
| CA3102841C (en) | General amyloid interaction motif (gaim) | |
| HK40110180A (en) | General amyloid interaction motif (gaim) | |
| HK40049127A (en) | General amyloid interaction motif (gaim) | |
| HK40049127B (en) | General amyloid interaction motif (gaim) | |
| EA046070B1 (ru) | Общий амилоид-взаимодействующий мотив (gaim) | |
| HK1213775B (en) | Use of p3 of bacteriophage fusion proteins as amyloid binding agents | |
| RS56559B1 (sr) | Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |